Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials

Journal of the National Cancer Institute

Volumn 93, Issue 16, 2001, Pages 1204-1214

  Seidenfeld, Jerome ^a   Piper, Margaret ^a   Flamm, Carole ^a   Hasselblad, Victor ^b   Armitage, James O ^c   Bennett, Charles L ^d   Gordon, Michael S ^e   Lichtin, Allan E ^f   Wade III, James L ^g   Woolf, Steven ^h   Aronson, Naomi ^a  

^a Blue Cross and Blue Shield Association   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Cancer Care Specialists   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; CANCER PATIENT; CANCER THERAPY; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DRUG COST; DRUG EFFECT; DRUG SENSITIVITY; DRUG USE; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS;

EID: 0035880780     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.16.1204     Document Type: Review

References (64)

1. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis
2. Erythropoietin therapy
3. Recombinant human erythropoietin and the anemia of cancer
4. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin
5. Evidence-based recommendations for the clinical use of recombinant human erythropoietin
6. Management of anemia in patients with cancer
7. Anemia in cancer patients
8. Anemia of cancer
9. Epoetin alfa and high-dose chemotherapy
10. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications
11. Chemotherapy-induced anemia in adults: Incidence and treatment
12. Transfusion requirements in patients with malignancy
13. The red cell transfusion trigger: Has a sin of commission now become a sin of omission?
14. Principles and practice of transfusion medicine
15. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis
16. Cost-effectiveness of human erythropoietin in the prevention of chemotherapy-induced anemia
17. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia
18. Use of erthropoietin in oncology
19. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
20. The hazards of scoring the quality of clinical trials for meta-analysis
21. Does quality of reports of randomised controlled trials affect estimates of intervention efficacy reported in meta-analyses?
22. Measuring the quality of trials: The quality of the quality scales
23. Improving the quality of reporting of randomized trials. The CONSORT statement
24. Recommendations for evaluating the validity of quality of life claims for labeling and promotion
25. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
26. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
27. Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life
28. Quality of life assessment in cancer clinical trials
29. Methodologic issues in assessing the quality of life of cancer patients
30. Lessons learned from measuring health-related quality of life in oncology
31. Quality-of-life end points in cancer clinical trials: The U.S. Food and Drug Administration perspective
32. Quality-of-life end points in oncology drug trials
33. Statistical methods for meta-analysis
34. FAST*PRO Software for meta-analysis by the confidence profile method
35. Meta-analysis in clinical trials
36. Meta-analysis of multi-treatment studies
37. An assessment of clinically useful measures of the consequences of treatment
38. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
39. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy
40. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
41. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study
42. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
43. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)
44. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial
45. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia
46. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
47. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors
48. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
49. The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy: Results of a double-blind, placebo-controlled clinical trial
50. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study
51. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy
52. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial
53. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
54. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
55. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children
56. Erythropoietin for patients undergoing radiotherapy: A pilot study
57. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin
58. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
59. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer
60. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
61. The Functional Assessment of Cancer Therapy - Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
62. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy